For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Inhibrx-INBRX-109 SA CS

Trial Overview

Official Title

A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma

Study Purpose

To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.

Diagnosis

Patients with unresectable or metastatic conventional chondrosarcoma.

Eligibility

Unresectable or metastatic conventional chondrosarcoma

Prior lines of therapy allowed except prior DR5 agonists.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

This is a multicenter, randomized, blinded, placebo-controlled study of intravenous INBRX-109 in patients with unresectable or metastatic conventional chondrosarcoma.

Study treatments, INBRX-109 or placebo, will be administered through IV infusions every three weeks.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Pending
Phase
Phase II
Methodist Health System Trial Code
INBRX